The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: An in-depth review
N Reich, C Hölscher - Frontiers in neuroscience, 2022 - frontiersin.org
Currently, there is no disease-modifying treatment available for Alzheimer's and Parkinson's
disease (AD and PD) and that includes the highly controversial approval of the Aβ-targeting …
disease (AD and PD) and that includes the highly controversial approval of the Aβ-targeting …
Sources and triggers of oxidative damage in neurodegeneration
PR Angelova - Free Radical Biology and Medicine, 2021 - Elsevier
Neurodegeneration describes a group of more than 300 neurological diseases,
characterised by neuronal loss and intra-or extracellular protein depositions, as key …
characterised by neuronal loss and intra-or extracellular protein depositions, as key …
Integrative network analysis of nineteen brain regions identifies molecular signatures and networks underlying selective regional vulnerability to Alzheimer's disease
Background Alzheimer's disease (AD) is the most common form of dementia, characterized
by progressive cognitive impairment and neurodegeneration. However, despite extensive …
by progressive cognitive impairment and neurodegeneration. However, despite extensive …
Unbiased metabolomic investigation of Alzheimer's disease brain points to dysregulation of mitochondrial aspartate metabolism
G Paglia, M Stocchero, S Cacciatore, S Lai… - Journal of Proteome …, 2016 - ACS Publications
Alzheimer's disease (AD) is the most common cause of adult dementia. Yet the complete set
of molecular changes accompanying this inexorable, neurodegenerative disease remains …
of molecular changes accompanying this inexorable, neurodegenerative disease remains …
Acylated ghrelin as a multi-targeted therapy for Alzheimer's and Parkinson's disease
N Reich, C Hölscher - Frontiers in Neuroscience, 2020 - frontiersin.org
Much thought has been given to the impact of Amyloid Beta, Tau and Alpha-Synuclein in the
development of Alzheimer's disease (AD) and Parkinson's disease (PD), yet the clinical …
development of Alzheimer's disease (AD) and Parkinson's disease (PD), yet the clinical …
[HTML][HTML] Cholecystokinin (CCK): a neuromodulator with therapeutic potential in Alzheimer's and Parkinson's disease
N Reich, C Hölscher - Frontiers in Neuroendocrinology, 2024 - Elsevier
Cholecystokinin (CCK) is a neuropeptide modulating digestion, glucose levels,
neurotransmitters and memory. Recent studies suggest that CCK exhibits neuroprotective …
neurotransmitters and memory. Recent studies suggest that CCK exhibits neuroprotective …
Ataxin-1 regulates the cerebellar bioenergetics proteome through the GSK3β-mTOR pathway which is altered in Spinocerebellar ataxia type 1 (SCA1)
I Sánchez, E Balague… - Human molecular …, 2016 - academic.oup.com
A polyglutamine expansion within the ataxin-1 protein (ATXN1) underlies spinocerebellar
ataxia type-1 (SCA1), a neurological disorder mainly characterized by ataxia and cerebellar …
ataxia type-1 (SCA1), a neurological disorder mainly characterized by ataxia and cerebellar …
Reduced mitochondrial activity is early and steady in the entorhinal cortex but it is mainly unmodified in the frontal cortex in Alzheimer's disease
M Armand-Ugon, B Ansoleaga… - Current Alzheimer …, 2017 - ingentaconnect.com
Background: It is well established that mitochondrial damage plays a role in the
pathophysiology of Alzheimer's disease (AD). However, studies carried out in humans …
pathophysiology of Alzheimer's disease (AD). However, studies carried out in humans …
Dihydrolipoamide dehydrogenase suppression induces human tau phosphorylation by increasing whole body glucose levels in a C. elegans model of Alzheimer's …
W Ahmad - Experimental brain research, 2018 - Springer
The microtubule associated tau protein becomes hyperphosphorylated in Alzheimer's
disease (AD). While hyperphosphorylation promotes neurodegeneration, the cause and …
disease (AD). While hyperphosphorylation promotes neurodegeneration, the cause and …
Metabolic characterization of intact cells reveals intracellular amyloid beta but not its precursor protein to reduce mitochondrial respiration
PM Schaefer, B von Einem, P Walther, E Calzia… - PloS one, 2016 - journals.plos.org
One hallmark of Alzheimer´ s disease are senile plaques consisting of amyloid beta (Aβ),
which derives from the processing of the amyloid precursor protein (APP). Mitochondrial …
which derives from the processing of the amyloid precursor protein (APP). Mitochondrial …